26
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Industry Efforts to Weaken the EPA's Classification of the Carcinogenicity of 1,3-Butadiene

Pages 378-383 | Published online: 19 Jul 2013

References

  • Huff JE, Melnick RL, Solleveld HA, Haseman JK, Powers M, Miller RA. Multiple organ carcinogenicity of 1,3-butadiene in B6C3F1 mice after 60 weeks of inhalation exposure. Science. 1985; 227: 548–9.
  • Melnick RL, Huff J. 1,3-Butadiene: toxicity and carcinogenicity in laboratory animals and in humans. Rev Environ Contam Tox-icol. 1992; 124: 11144.
  • Melnick RL, Shackelford CC, Huff J. Carcinogenicity of 1,3-butadiene. Environ Health Perspect. 1993; 100: 227–36.
  • Melnick RL, Huff JE. 1,3-Butadiene induces cancer in experi-mental animals at all concentrations from 6.25 to 8000 parts per million. IARC Sci Publ. 1993; 127: 309-22.
  • Melnick RL, HuffJ, Chou BJ, Muller RA. Carcinogenicity of 1,3-butadiene in C57BL/6 x C3J Fl mice at low exposure concen-trations. Cancer Res. 1990; 50: 6592–9.
  • Macaluso M, Larson R, Delzell E, et al. Leukemia and cumula-tive exposure to butadiene, styrene and benzene among work-ers in the synthetic rubber industry. Toxicology. 1996; 113 (1-3): 190–202.
  • Matanoski G, Elliott E, Tao X, Francis M, Correa-Villasenor A, Santos-Burgoa C. Lymphohematopoietic cancers and butadiene and styrene exposure in synthetic rubber manufacture. Ann NY Acad Sci. 1997; 837: 157–69.
  • Ward JB Jr, Abdel-Rahman SZ, Henderson RE et al. Assessment of butadiene exposure in synthetic rubber manufacturing workers in Texas using frequencies of hprt mutant lymphocytes as a biomarker. Chem Biol Interact. 2001;135-6: 465-83.
  • Report on Carcinogens. 10th ed. U.S. Department of Health and Human Services, Public Health Service, National Toxicol-ogy Program, December 2002.
  • Consensus Review Draft Health Assessment of 1,3-Butadiene. U.S. Environmental Protection Agency, Washington, DC, Janu-ary 2001. Report number EPA/600/P-98/001B:Section 10.11.14.
  • Toxics Release Inventory. TRI On-site and Off-site Reported Dis-posed of or Otherwise Released (in pounds), for facilities in All Industries, 1,3-Butadiene, U.S. Environmental Protection Agency, 2002.
  • Environmental Defense Scorecard. Industrial sectors with reported total environmental releases for 1,3-butadiene. For chemical profile see http://www.scorecarcl.org/chemical-profiles/index.tcl.2004. For hazard ranking see http://www.scorecard.org/chemical-profiles/hazard-indicators.tcl?edfsubstance_id=106%2d99%2d0.
  • Knox EG. Childhood cancers and atmospheric carcinogens. J Epidemiol Community Health. 2005; 59: 101–5.
  • Phibbs P. EPA to reform management of database used for fed-eral, state regulations. The Bureau of National Affairs, Inc. Washington, DC, September 3. 2002; 170: B–1.
  • Environmental Protection Agency, Integrated Risk Information System (IRIS). http://www.epa.gov/reports/objects/iriswebp/iriswebp/iriswebp.
  • Environmental Protection Agency. Integrated Risk Information System (IRIS) Substance file for 1,3 butadiene. 2002. http://www.epa.gov/tri/.
  • Delzell E, Sathiakumar N, Hovinga M, et al. A follow-up study of synthetic rubber workers. Toxicology. 1996; 113 (1-3): 182–9.
  • Ward EM, Fajen JM, Ruder AM, Rinsky RA, Halperin WE, Fessler-Fiesch CA. Mortality study of workers in 1,3-butadiene production units identified from a chemical workers cohort. Environ Health Perspect. 1995; 103: 598–603.
  • Ward EM, Fajen JM, Ruder AM, Rinsky RA, Halperin WE, Fessler-Flesch CA. Mortality study of workers employed in 1,3-butadiene production units identified from a large chemical workers cohort. Toxicology. 1996; 113 (1-3): 157–68.
  • Occupational Safety and Health Administration. Occupational Exposure to 1,3-Butadiene, Final Rule. Fed Reg. 1996; 61: 56746-856.
  • Infante P. Safeguarding scientific evaluations by governmental agencies: case study of OSHA and the 1,3-Butadiene classifica-tion. Int J Occup Env Health. 2005; 11: 372–7.
  • An SAB report: Review of the health risk assessment of 1,3-buta-diene. U.S. Environmental Protection Agency: Science Advisory Board (SAB), Washington, DC, November 19. 1998; Report number EPA-SAB-EHC-99-003. http://www.epa.gov/sab/ehc9903.pdf.
  • Grumet J. Letter from Executive Director, Northeast States for Coordinated Air Use Management (NSCAUM), to Noonan N, U.S. Environmental Protection Agency, expressing concern regarding the Butadiene Draft Health Risk Assessment, June 7. 1999. Report number January 1998/E0A/600/P-98/001A.
  • Brown JP, Collins JF, Salmon AG, Budroe JD. Letter from Cali-fornia Environmental Protection Agency scientists to A. Kop-pikar, U.S. EPA, raising concern regarding the 1998 Preliminary Draft Health risk assessment of 1,3-butadiene, July 8. 1999
  • Sass J, Greer L, Devine J. Letter from the Natural Resources Defense Council (NRDC) to Farland W, U.S. EPA, raising con-cern about the 2001 consensus review draft Health Assessment for 1,3-Butadiene, June 15. 2001. EPA Report number EPA/ 600/P-98/001B, January 2001.
  • EPA's Scientific Advisory Board Panels. Improved Policies and Procedures Needed to Ensure Independence and Balance. U.S. General Accounting Office, Washington, DC, June 2001. Report number GA0-01-536.
  • Tomatis L. The IARC monographs program: changing attitudes towards public health. Int J Occup Environ Health. 2002; 8: 144–52.
  • Axelson O, Castleman B, Epstein S, et al. Re: Implementation of WHO Guidelines on Disclosure of Interest by members of WHO Expert Panels. Int J Occup Environ Health. 2002; 8: 271–3.
  • Sass J. Lead IARC towards compliance with WHO/IARC Decla-ration of Interests (DOI) policy. Int J Occup Environ Health. 2002; 8: 277–8.
  • Sass J. Continued insensitivity to conflicts of interest at IARC. bat J Occup Environ Health. 2003; 9: 88–9; discussion 89.
  • Sass JB, Greer L. Re: concern that working group members who will be assessing styrene have financial conflicts of interest. Int J Occup Environ Health. 2002; 8: 153–5.
  • Melnick RL. Suppression of crucial information in the IARC evaluation of DEHP. Int J Occup Environ Health. 2003; 9: 84–5; discussion 89.
  • Huff J. IARC monographs, industry influence, and upgrading,downgrading, and under-grading chemicals: a personal point of view. International Agency for Research on Cancer. Int J Occup Environ Health. 2002; 8: 249–70.
  • Editorial. Transparency at IARC. Lancet. 2003; 361: 189.
  • Cogliano VJ, Baan PA, Strait' K, et al. The science and practice of carcinogen identification and evaluation. Environ Health Perspect. 2004; 112: 1269–74.
  • Blackburn E. Bioethics and the political distortion of biomed-ical science. N Engl J Med. 2004; 350: 1379–80.
  • Steinbrook R. Science, politics, and federal advisory commit-tees. N Engl J Med. 2004; 350: 1454–60.
  • Brumfiel G. US science policy: mission impossible? Nature. 2004; 428: 250–1.
  • Union of Concerned Scientists. http://www.ucsusa.org/global_environment/rsi/page.cfm?pageid=1320. 2004.
  • Editorial. Keeping scientific advice non-partisan. Lancet. 2002;360:1525,
  • All the President's yes-men? Nature. 2003; 421: 459.
  • Train ER. When politics trumps science (letter to the editor), New York Times, June 21, 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.